Recruiting
Von Willebrand's disease+1
RecruitingPhase 2 Study of ALN-6400 Safety and Tolerability in Female Patients with Von Willebrand Disease and Heavy Menstrual Bleeding
InvestigationalNo placebo
Phase 2 Study of ALN-6400 Safety and Tolerability in Female Patients with Von Willebrand Disease and Heavy Menstrual Bleeding
InvestigationalNo placebo
- Disease:Von Willebrand's diseaseHeavy menstrual bleeding
- Substances:–
Countries:
Germany
Germany- Participants:18–64 years
- Sponsor:Alnylam Pharmaceuticals Inc.
